Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling

Journal of Pharmaceutical Sciences

Volumn 87, Issue 7, 1998, Pages 813-820

  Gårdmark, Marie ^a   Karlsson, Mats O ^a   Jonsson, Fredrik ^a,b   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BREATHING MECHANICS; CANCER PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; MALE; NONHUMAN; POSTOPERATIVE PAIN; RAT; RESPIRATION DEPRESSION;

EID: 0031826786     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980056f     Document Type: Article

References (62)

1. Gong, Q.; Hedner, J.; Björkman, R.; Hedner, T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992, 48, 249-255.
2. Ekblom, M.; Gårdmark, M.; Hammarlund-Udenaes M. Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive ettect of morphine. Biopharm. Drug Disp. 1993, 14, 1-11.
3. Barjavel, M. J.; Scherrmann, J.-M.; Bhargava, H. N. Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study. Br. J. Pharmacol. 1995, 116, 3205-3210.
4. Smith, M. T.; Watt, J. A.; Cramond, T. Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci. 1990, 47, 579-585.
5. Suzuki, N.; Kalso, E.; Rosenberg, P. H. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur. J. Pharmacol. 1993, 249, 247-250.
6. Hewett, K.; Dickenson, A. H.; McQuay, H. J. Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993, 53, 59-63.
7. Ouellet, D. M.; Pollack, G. M. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem. Pharmacol. 1997, 53, 1451-1457.
8. Lipkowski, A. W.; Carr, D. B.; Langlade, A.; Osgood, P. F.; Szyfelbein, S. K. Morphine-3-glucuronide: silent regulator of morphine actions. Life Sci. 1994, 55, 149-154.
9. Labella, F.; Pinsky, C.; Havlicek, V. Morphine derivatives with diminished opiate receptor potency show central excitatory activity. Brain Res. 1979, 174, 263-271.
10. Gong, Q.; Hedner, T.; Hedner, J.; Björkman, R.; Nordberg, G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur. J. Pharmacol. 1991, 193, 47-53.
11. Bartlett, S. E.; Cramond, T.; Smith, M. T. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci. 1994, 54, 687-694.
12. Yaksh, T.; Harty, G.; Onofrio, B. High doses of spinal morphine produce a nonopiate receptor-mediated hyperestheisia: Clinical and theoretic implications. Anestheiology 1986, 64, 590-597.
13. Wolff, J.; Bigler, D.; Broen Christensen, C.; Rasmussen S. N.; Andersen H. B.; Tonnesen, K. H. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur. J. Clin. Pharmacol. 1988, 34, 353-357.
14. Yaksh, T. L.; Harty, G. J. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J. Pharmacol. Exp. Ther. 1988, 244, 501-507.
15. Pasternak, G. W.; Bodnar, R. J.; Clark, J. A.; Inturrisi, C. E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987, 41, 2845-2849.
16. Oguri, K.; Yamanda-Mori, I.; Shigezane, J.; Hirano, T.; Yoshimura, H. Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci. 1987, 41, 1457-1464.
17. Christensen, C. B.; Jørgensen, L. Morphine-6-glucuronide has high affinity for the opoid receptor. Pharmacol. Toxicol. 1987, 60, 75-76.
18. Shimomura, K.; Kamata, O.; Ueki, S.; Ida, S.; Oguri, K.; Yoshimura, H.; Tsukamoto, H. Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med. 1971, 105, 45-52.
19. Coughtrie, M. W. H.; Ask, B.; Rane, A.; Burchell, B.; Hume, R. The enantioselective glucuronidation of morphine in rats and humans. Biochem. Pharmacol. 1989, 38, 3273-3280.
20. Oguri, K.; Hanioka, N.; Yoshimura, H. Species differences in metabolism of codeine: urinary excretion of codeine glucuronide, morphine-3-glucuronide and morphine-6-glucuronide in mice, rats, guinea pigs and rabbits. Xenobiotica 1990, 20, 683-688.
21. Kuo, C. K.; Hanioka, N.; Hoshikawa, Y.; Oguri, K.; Yoshimura, H. Species difference of site-selective glucuronidation of morphine. J. Pharmacobiodyn. 1991, 14, 187-193.
22. Rosenfeld G. C.; Burks, T. F. Single-dose tolerance to morphine hypothermia in the rat: differentiation of acute from long-term tolerance. J. Pharmacol. Exp. Ther. 1977, 402, 654-659.
23. Kissin, I.; Brown, P. T.; Robinson, A.; Bradley, E. L. Acute tolerance in morphine analgesia: continuous infusion and single injection in rats. Anesthesiology 1991, 74, 166-171.
24. Martin, W. R.; Eades, C. G. Demonstration of tolerance and physical dependence in the dog following a short-term infusion of morphine. J. Pharmacol. Exp. Ther. 1961, 133, 262-270.
25. Cox, B. M.; Ginsburg, M.; Osman, O. H. Acute tolerance to narcotic analagesic drugs in rats. Br. J. Pharmacol. Chemother. 1968, 33, 245-256.
26. Ling, G. S. F.; Paul, D.; Simantov, R.; Pasternak, G. W. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci. 1989, 45, 1627-1636.
27. Gårdmark, M.; Ekblom, M.; Bouw, R.; Hammarlund-Udenaes, M. Quantification of effect delay and acute tolerance development to morphine in the rat. J. Pharmacol. Exp. Ther. 1993, 267, 1061-1067.
28. Smith, G. D.; Smith, M. T. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 1995, 62, 51-60.
29. Pelligrino, D.; Riegler, F.; Albrecht, R. Ventilatory effects of fourth cerebroventricular infusions of morphine-6-or morphine-3-glucoronide in the awake dog. Anesthesiolgy 1989, 71, 936-940.
30. Ouellet, D. M.-C.; Pollack, G. M. A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. J. Pharmacokin. Biopharm. 1995, 23, 531-549.
31. Ekblom, M.; Hammarlund-Udenaes, M.; Paalzow, L. Tolerance development and rebound effects of morphine in relation to different administrations in rats. J.Pharmacol. Exp. Ther. 1993, 266, 244-252.
32. Joel, S. P.; Osborne, R. J.; Slevin, M. L. An improved method tor the simultaneous determination of morphine and its principal glucuronide metabolites. J. Chromatogr. 1988, 430, 394-399.
33. Drost, R. H.; van Ooijen, R. D. Determination of morphine in serum and cerebrospinal fluid by gas chromatography and selected ion monitoring after reversed-phase column extraction. J. Chromatogr. 1984, 310, 193-198.
34. Carroll, M. N.; Lim, R. K. S. Observation on the neuropharmacology of morphine and morphinelike analgesia. Arch. Int. Pharmacodyn. Ther. 1960, 125, 383-403.
35. Paalzow, G.; Paalzow, L. The effects of caffeine and theophylline on nociceptive stimulation in the rat. Acta Pharmacol. Toxicol. 1973, 32, 22-32.
36. Gibaldi, M.; Perrier, D. In Pharmacokinetics, 2nd ed.; Swarbrick J. Ed.; Marcel Dekker Inc.: Chapel Hill, NC, 1982; pp 63-65.
37. Beal, S. L.; Sheiner, L. B. NONMEM User's Guides, NON-MEM Project Group, University of California at San Fransisco, San Fransisco, 1992.
38. Jonsson, E. N.; Karlsson, M. O. Manual of Xpose, Faculty of Pharmacy, Uppsala University, http://www.biof.uu.se/xpose, 1996.
39. Porchet, H. C.; Benowitz, N. L.; Sheiner, L. B. Pharmacodynamic model of tolerance: application to nicotine. J. Pharmacol. Exp. Ther. 1988, 244, 231-236.
40. Ariens, E. J.; Simonis, A. M. A molecular basis for drug action. J. Pharm. Pharmacol. 1964, 16, 137-157.
41. Ariens, E. J.; Simonis, A. M. A molecular basis for drug action. The interaction of one or more drugs with different receptors. J. Pharm. Pharmacol. 1964, 16, 289-312.
42. Dayneka, N. L.; Garg, V.; Jusko, W. J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokmet. Biopharm. 1993, 21, 457-478.
43. Jusko, W. J.; Ko, H. C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 1994, 56, 406-419.
44. Movin-Osswald, G.; Hammarlund-Udenaes, M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra-and interindividual aspects. J. Pharmacol. Exp. Ther. 1995, 274, 921-927.
45. Ekblad, E. B. M.; Licko, V. A model eliciting transient responses. Am. J. Physiol. 1984, 246, R114-R121.
46. Mandema, J. W.; Wada, D. R. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alternative in the rat. J. Pharmacol. Exp. Ther. 1995, 275, 1185-1194.
47. Chen, Z.; Irvine, R.; Somogyi, A.; Bochner, F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 1991, 48, 2165-2171.
48. Bartlett, S. E.; Dodd, P. R.; Smith, M. T. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol. Toxicol. 1994, 75, 73-81.
49. Woolf, C. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res. 1981, 209, 491-495.
50. Bartlett, S. E.; Smith, M. T. Effects of morphine-3-glucuronide and morphine on the K+-evoked release of [3H]-glutamic acid and [14C]-gamma-aminobutyric acid from rat brain synaptosomes. Life Sci. 1996, 58, 447-454.
51. Hammarlund, M. M.; Odlind, B.; Paalzow, L. K. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 1985, 233, 447-453.
52. Langerman, L.; Zakowski, M. I.; Piskoun, B.; Grant G. J. Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusions in the rat model. J. Pharmacol. Toxicol. Methods 1995, 34, 23-27.
53. Murphey, L. J.; Olsen, G. D. Morphine-6-beta-D-glucuronide respiratory pharmacodynamics in the neonatal guinea pig. J. Pharmacol. Exp. Ther. 1994, 268, 110-116.
54. McQuay, H. J.; Carroll, D.; Faura, C. C.; Gavaghan, D. J.; Hand, C. W.; Moore, R. A. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin. Pharmacol. Ther. 1990, 48, 236-244.
55. Hasselström, J ; Säwe, J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations Clin. Pharmacokinet. 1993, 24, 344-354.
56. Goucke, C. R.; Hackett, L. P.; Ilett, K. F. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuromde in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 1994, 56, 145-149.
57. D'Honneur, G.; Gilton, A.; Sandouk, P.; Scherrmann, J. M.; Duvaldestin, P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994, 81, 87-93.
58. Sawe J.; Svensson, J. O.; Odar, C. I. Kinetics of morphine in patients with renal failure [letter]. Lancet 1985, 2, 211.
59. Osborne, R.; Joel, S.; Grebenik, K.; Trew, D.; Slevin, M, The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin. Pharmacol. Ther. 1993, 54, 158-167.
60. Wolff, T.; Samuelsson, H.; Hedner, T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995, 62, 147-154.
61. Sjogren, P.; Jonsson, T.; Jensen, N. H.; Drenck, N. E.; Jensen, T. S. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993, 55, 93-97.
62. Sjøgren, P.; Jensen, N.-H.; Staehelin Jensen, T. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994, 59, 313-316.